Evonile Pharma (formerly Novartis India) has initiated a postal ballot to approve stock options for its CEO, Dr. Vikas Gupta, and to authorize asset-backed borrowing up to Rs 1,500 crore. Shareholders can cast e-votes until November 12, 2026, with results expected by November 14.
Evonile Pharma Announces Postal Ballot for Key Strategic Resolutions
Resolutions involve CEO ESOPs and a Rs 1,500 crore borrowing limit authorization.
E-voting commences October 14, 2026, and concludes November 12, 2026.
Reader Takeaway: Executive compensation via ESOPs and expanded borrowing powers signal readiness for future operational or strategic expansion.
What just happened
Evonile Pharma Limited, formerly known as Novartis India Limited, has issued a postal ballot notice to its shareholders. The company is seeking approval for two special resolutions. The first relates to the 'Employee Stock Option Scheme 2026,' specifically covering the grant of options to the newly appointed Managing Director and CEO, Dr. Vikas Gupta. The second resolution seeks authorization to create charges, mortgages, or pledges on company assets to secure borrowings of up to Rs 1,500 crore.
Why this matters
The vote on stock options aligns the leadership’s compensation with long-term performance, while the asset-charge authorization under Section 180(1)(a) of the Companies Act provides the company with a credit facility ceiling. The Rs 1,500 crore limit serves as a strategic buffer for potential capital requirements, debt restructuring, or future business needs.
The backstory
This move follows the leadership transition earlier this year, with Dr. Vikas Gupta assuming the roles of MD and CEO effective July 29, 2026. The shift in company identity from Novartis India to Evonile Pharma marks a new phase in its corporate journey, and this postal ballot is part of establishing the governing frameworks under the current leadership team.
Important Dates for Investors
- Cut-off date for voting eligibility: October 9, 2026
- Remote e-voting period: October 14, 2026 (9:00 AM) to November 12, 2026 (5:00 PM)
- Result declaration: By November 14, 2026
What to track next
Shareholders should monitor the passage of these special resolutions, which require a 75% majority vote to succeed. Following the result announcement on November 14, the company is expected to formalize the borrowing framework and proceed with the designated option grants for the CEO.